RGS6 as a Novel Therapeutic Target in CNS Diseases and Cancer

Journal Title: The AAPS Journal - Year 2016, Vol 18, Issue 3

Abstract

Regulator of G protein signaling (RGS) proteins are gatekeepers regulating the cellular responses induced by G protein-coupled receptor (GPCR)-mediated activation of heterotrimeric G proteins. Specifically, RGS proteins determine the magnitude and duration of GPCR signaling by acting as a GTPase-activating protein for Gα subunits, an activity facilitated by their semiconserved RGS domain. The R7 subfamily of RGS proteins is distinguished by two unique domains, DEP/DHEX and GGL, which mediate membrane targeting and stability of these proteins. RGS6, a member of the R7 subfamily, has been shown to specifically modulate Gαi/o protein activity which is critically important in the central nervous system (CNS) for neuronal responses to a wide array of neurotransmitters. As such, RGS6 has been implicated in several CNS pathologies associated with altered neurotransmission, including the following: alcoholism, anxiety/depression, and Parkinson’s disease. In addition, unlike other members of the R7 subfamily, RGS6 has been shown to regulate G protein-independent signaling mechanisms which appear to promote both apoptotic and growth-suppressive pathways that are important in its tumor suppressor function in breast and possibly other tissues. Further highlighting the importance of RGS6 as a target in cancer, RGS6 mediates the chemotherapeutic actions of doxorubicin and blocks reticular activating system (Ras)-induced cellular transformation by promoting degradation of DNA (cytosine-5)-methyltransferase 1 (DNMT1) to prevent its silencing of pro-apoptotic and tumor suppressor genes. Together, these findings demonstrate the critical role of RGS6 in regulating both G protein-dependent CNS pathology and G protein-independent cancer pathology implicating RGS6 as a novel therapeutic target.

Authors and Affiliations

Katelin E. Ahlers, Bandana Chakravarti, Rory A. Fisher

Keywords

Related Articles

Translating Human Effective Jejunal Intestinal Permeability to Surface-Dependent Intrinsic Permeability: a Pragmatic Method for a More Mechanistic Prediction of Regional Oral Drug Absorption

The online version of this article (doi:10.1208/s12248-015-9758-0) contains supplementary material, which is available to authorized users.

Performance and Robustness of the Monte Carlo Importance Sampling Algorithm Using Parallelized S-ADAPT for Basic and Complex Mechanistic Models

The Monte Carlo Parametric Expectation Maximization (MC-PEM) algorithm can approximate the true log-likelihood as precisely as needed and is efficiently parallelizable. Our objectives were to evaluate an importance sampl...

Regulatory Considerations for Approval of Generic Inhalation Drug Products in the US, EU, Brazil, China, and India

This article describes regulatory approaches for approval of “generic” orally inhaled drug products (OIDPs) in the United States, European Union, Brazil, China and India. While registration of a generic O...

Reference Datasets for Bioequivalence Trials in a Two-Group Parallel Design

The online version of this article (doi:10.1208/s12248-014-9704-6) contains supplementary material, which is available to authorized users.

Population Pharmacokinetic Modeling of the Enterohepatic Recirculation of Fimasartan in Rats, Dogs, and Humans

The online version of this article (doi:10.1208/s12248-015-9764-2) contains supplementary material, which is available to authorized users.

Download PDF file
  • EP ID EP680865
  • DOI  10.1208/s12248-016-9899-9
  • Views 55
  • Downloads 0

How To Cite

Katelin E. Ahlers, Bandana Chakravarti, Rory A. Fisher (2016). RGS6 as a Novel Therapeutic Target in CNS Diseases and Cancer. The AAPS Journal, 18(3), -. https://europub.co.uk/articles/-A-680865